Browse by Medical Category
Lab phone: 617-726-1274
Watch Carmen Foundation Video
Alex Kazantsev, PhD, Huntington's and Parkinson's disease drug discovery research
Research Investigator Profile
Aleksey G. Kazantsev, PhD
My laboratory is focused on discovery therapeutic agents for Huntington's and Parkinson's diseases using methods of high throughput screening, rational drug design, and medicinal chemistry lead optimization. We employ diverse approaches for small molecule targeting various pathophysiologic pathways of neurodegeneration. We conduct early stages of drug discovery in cellular models of neurodegeneration, and assess animal efficacy of identified promising molecules in disease rodent models. Our overall goal is to advance candidates emerged form these studies for therapeutic clinical development.
We have had early success using this strategy and discovered a novel compound, C2-8, that decreases aggregation in a cell-based assay of huntingtin aggregation. The compound was found to improve behavior, decrease aggregation and decrease neuronal atrophy in a mouse model of Huntington's disease.
Recently we identified drugs, the inhibitors od SIRT2 decaetylase, protecting dopamine neurons from alpha-synuclein induced cell death in vitro and in vivo in models of Parkinson's disease. Human deacetylase SIRT2, one of seven human sirtuins, regulates acetylation of tubulin and thereby affects the cytoskeleton and neuronal plasticity. Currently brain-permeable SIRT2 inhibitors start emerging from structure activity relationship studies. Efficacy animal trials are planned once the safety and tolerability of the new agents is explored.
Huntington's and Parkinson's diseases
High throughput screening, rational drug design, and medicinal chemistry lead optimizatio
Back to Top